ストックスクリーナーアプリを入手
11.45
1.38%
-0.16
プレマーケット:
11.29
-0.16
-1.40%
Oculis Holding Ag (OCS) 最新ニュース
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com
Oculis executive Sylvia Cheung reports June 10 share purchase - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment - Streetwise Reports
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles - AOL.com
OCS News | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill
Oculis shelves FDA filing after phase 3 DME trials miss key vision goals - MSN
Oculis enrolls first patient in licaminlimab PREDICT-1 DED trial - Optometry Times
Oculis to present neuroprotective drug Privosegtor at Clinical Trials Summit 2026 - Pluang
Oculis to present Privosegtor's progress for optic neuritis treatment at Clinical Trials Summit 2026 - Pluang
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm - PR Newswire
H.C. Wainwright reiterates Oculis stock rating on trial start - Investing.com UK
H.C. Wainwright reiterates Oculis stock rating on trial start By Investing.com - Investing.com Australia
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - The Manila Times
Oculis Holding AG to Present on Privosegtor at Clinical Trials at the Summit 2026 - Quiver Quantitative
Experimental eye drug Privosegtor aims to protect vision in optic neuritis - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Oculis Holding AG (OCS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Oculis executive and board member buys more company shares - Stock Titan
Oculis randomizes first patient in precision dry eye disease trial - grafa.com
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease - The Manila Times
New dry eye trial tailors licaminlimab to genes; only 13% see sustained relief - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Oculis to present updates on late-stage eye disease treatments at Goldman Sachs Healthcare Conference - Pluang
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference - The Manila Times
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud I - GuruFocus
Oculis Holding AG to Provide Update on Late-Stage Portfolio at 47th Annual Goldman Sachs Global Healthcare Conference - Quiver Quantitative
Price-Driven Insight from (OCS) for Rule-Based Strategy - Stock Traders Daily
2026-06-08 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Investors to Learn More About the Investigation | NDAQ:OCS | Press Release - Stockhouse
Oculis Holding AG (OCS) Securities Fraud InvestigationLevi & Korsinsky - Morningstar
Nan Fung Group Cuts Oculis Stake Amid Phase 3 Trial Failure and Stock DeclineNews and Statistics - IndexBox
Lost Money on Oculis Holding AG (OCS)? Contact Levi & Korsinsky About Investigation - TMX Newsfile
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Gross - The National Law Review
2026-06-07 | Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:OCS | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Oculis Holding AG (OCS) And Encourages Stockholders to Reach Out - ACCESS Newswire
2026-06-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Oculis Holding AG (OCS) And Encourages Stockholders to Reach Out | NDAQ:OCS | Press Release - Stockhouse
Oculis Holding (OCS) Is Down 60.1% After OCS-01 Trial Failure And Pipeline Pivot – Has The Bull Case Changed? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Stockholders to Connect - ACCESS Newswire
OCS Stock Price and Chart — NASDAQ:OCS - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AGOCS - PR Newswire
Levi & Korsinsky Announces Investigation of Securities Claims Against Oculis Holding AG (OCS) - GlobeNewswire
OCS Maintained by JP Morgan -- Price Target Lowered to $23.00 - GuruFocus
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-06-03 | Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:OCS | Press Release - Stockhouse
OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud - Business Wire
OCS Maintains by Baird -- Price Target Lowered to $38.00 - GuruFocus
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):